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Abstract
Data on therapy of COVID-19 in immunocompetent and immunosuppressed children are scarce. We aimed to explore man-
agement strategies of pediatric rheumatologists. All subscribers to international Pediatric Rheumatology Bulletin Board 
were invited to take part in an online survey on therapeutic approaches to COVID-19 in healthy children and children 
with autoimmune/inflammatory diseases (AID). Off-label therapies would be considered by 90.3% of the 93 participating 
respondents. In stable patients with COVID-19 on oxygen supply (stage I), use of remdesivir (48.3%), azithromycin (26.6%), 
oral corticosteroids (25.4%) and/or hydroxychloroquine (21.9%) would be recommended. In case of early signs of “cytokine 
storm” (stage II) or in critically ill patients (stage III) (a) anakinra (79.5% stage II; 83.6% stage III) or tocilizumab (58.0% 
and 87.0%, respectively); (b) corticosteroids (oral 67.2% stage II, intravenously 81.7% stage III); (c) intravenous immuno-
globulins (both stages 56.5%); or (d) remdesivir (both stages 46.7%) were considered. In AID, > 94.2% of the respondents 
would not support a preventive adaptation of the immunomodulating therapy. In case of mild COVID-19, more than 50% 
of the respondents would continue pre-existing treatment with immunoglobulins (100%), hydroxychloroquine (94.2%), 
anakinra (79.2%) or canakinumab (72.5%), or tocilizumab (69.8%). Long-term corticosteroids would be reduced by 26.9% 
(< = 2 mg/kg/d) and 50.0% (> 2 mg/kg/day), respectively, with only 5.8% of respondents voting to discontinue the therapy. 
Conversely, more than 75% of respondents would refrain from administering cyclophosphamide and anti-CD20-antibodies. 
As evidence on management of pediatric COVID-19 is incomplete, continuous and critical expert opinion and knowledge 
exchange is helpful.
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Abbreviations
ACR  American College of Rheumatology
ADE  Antibody dependent enhancement
AID  Autoimmune/inflammatory disease
COVID-19  Corona virus disease 2019
FDA  Food and Drug Administration
HCQ  Hydroxychloroquine
IVIG  Intravenous immunoglobulins
JAK  Janus kinase
MERS  Middle east respiratory syndrome 
coronavirus
SARS  Severe acute respiratory syndrome 
coronavirus
Introduction
The newly emerged coronavirus SARS-CoV-2 (severe acute 
respiratory syndrome coronavirus 2) is the infectious patho-
gen causing COVID-19 (corona virus disease 2019), a pan-
demic that poses a threat to millions of lives and, therefore, a 
challenge to healthcare providers of all medical specialities. 
It became apparent that the shared expertise of rheumatolo-
gists and clinical immunologists is critical in the treatment 
of COVID-19 patients, as a significant proportion of adult 
and few pediatric patients develop hyperinflammatory dis-
ease [1–7].
While the course of COVID-19 in healthy children is 
usually asymptomatic or mild when compared to adults [8, 
9], a hyperinflammation syndrome (pediatric inflamma-
tory multisystem syndrome: PIMS or MIS-C: multisystem 
inflammatory syndrome in children) timely associated with 
SARS-CoV-2 has been described in a subset of pediatric 
patients in Europe and North America [2, 10–13]. Although 
patients with pediatric autoimmune/inflammatory disease 
(AID) may be more susceptible to virus infections when 
compared to age-matched healthy cohorts, and AID patients-
receiving immunomodulatory or immunosuppressive ther-
apy are considered to be more susceptible towards viral and 
bacterial infections [14, 15], there is no reliable evidence 
to suggest a higher risk of SARS-CoV-2 infection or more 
severe disease in those patients [4, 16–21]. Whether immune 
deficiency and/or immunomodulating treatment may even 
prevent severe complications such as PIMS-TS/MIS-C 
remains unclear [22]. Thus, in the absence of prospective 
studies in large cohorts, management of patients-receiving 
immunosuppression/modulation remains a particular chal-
lenge, as data are preliminary and somewhat conflicting as 
to whether or which type of immunomodulation represents 
a risk or protective factor for developing hyperinflammatory 
complications [1, 3, 4, 23, 24]. Published COVID-19-related 
recommendations providing clinical guidance for the man-
agement of children and adolescents [25–31] are largely 
based on case series, retrospective cohort studies, patho-
physiological considerations, or are derived from data on 
adult populations. As low-quality evidence and expert opin-
ion prevail, continuous inter-collegial discussion facilitate 
clinical decision making.
Here, we present results of an online opinion poll among 
international pediatric rheumatologists on: (a) possible gen-
eral therapy concepts in COVID-19 in children and adoles-
cents and (b) clinical management of pediatric patients with 
AID-receiving immunomodulation treatment in the context 
of SARS-CoV-2 pandemic.
Methods
The survey collecting opinions within the international pedi-
atric rheumatology community was conducted in line with 
the published recommendations for survey-based research 
[32].
Pediatric rheumatology professionals (1849 unique email 
addresses), subscribers to the international online Pediatric 
Rheumatology Bulletin Board administered at McMaster 
University in Canada (https ://mailm an.mcmas ter.ca/mailm 
an/listi nfo/ped-rhe-list), were invited to participate in the 
survey via an email distribution list. The survey form was 
put online using SurveyMonkey ® (https ://www.surve 
ymonk ey.com) and was open for response from May 28 to 
June 11, 2020. The participation was voluntary, no incen-
tives were used. One reminder email was distributed. The 
exact wording of the online survey form is available at Sup-
plementary Figure S1.
Data on respondents’ institutions, their experience in 
pediatric rheumatology (in years) and their practical expe-
rience with the care of COVID-19 patients were collected. 
Respondents could express their readiness to consider use 
of (off-label) therapies in COVID-19-affected cases. A list 
of suggested drugs (see Fig. 1) was provided in alphabeti-
cal order. Potential treatment choices were available for in-
patients stratified by COVID-19 disease severity:
(i) Stage I: pneumonia with oxygen demand; (ii) Stage 
II: additional respiratory deterioration and/or imminent 
cytokine storm; (iii) Stage III: a critically ill patient with 
acute respiratory distress syndrome or multiorgan failure.
Respondents could express their disapproval with the 
use of a particular drug at any stage of the disease (“I 
would not recommend this drug”). In case of uncertainty, 
a statement “I do not know” could be selected. In case of 
treating a patient with an increased risk of severe viral 
disease (e.g. a patient with relevant immunodeficiency 
or severe cardiopulmonary, nephrological or neurode-
generative underlying disease), respondents were asked 
whether they would choose the following therapies 
earlier in the course of the disease: (a) antiviral drugs; 
913Rheumatology International (2021) 41:911–920 
1 3
(b) corticosteroids; (c) immunomodulatory drugs; (d) 
cytokine blockade; (e) immunoglobulins; or (f) convales-
cent plasma.
Treatment options for PIMS/MIS-C were not specifically 
addressed in this survey.
In the second part of the survey, the approach to anti-
inflammatory, immunomodulatory/immunosuppressive ther-
apy in patients with AID in the context of COVID-19 was 
addressed. First, respondents could report on their attitude 
towards preventive adaptation of the ongoing treatment for 
children with AID in the absence of SARS-CoV-2 exposure 
or infection. Second, respondents’ treatment strategies in 
patients with mild symptoms of proven COVID-19 were 
addressed (list of the drugs in Fig. 2). Possible response 
options included “no change”, “reducing” or “stop” the long-
term medication.
Close-ended answer choices were applied in all questions. 
The online survey form was subjected to internal validation. 
Data anonymity were warranted.
Statistical analysis
Only complete datasets (including respondents’ character-
istics, responses from part one and/or two) were subjects to 
analysis. Statistical analysis was performed using R (v 4.0.0) 
and the tidyverse packages dplyr (v 1.0.2). Graphics were 
generated using the R package ggplot2 (v 3.3.2). Double-
sided Fisher’s exact test was applied to compare frequencies 
of particular responses between different participant groups.
Ethics statement
The study was exempt from ethical review while no patients 
or study subjects were involved. Only anonymous demo-
graphic and expert opinion data were collected. The respond-
ents were made aware in the text of the invitation email that 
the results of the survey will be eventually published.
Fig. 1  Therapeutics considered for pediatric COVID-19. The number 
of respondents expressing their opinion on each treatment option is 
depicted in each line next to the drug name; number of respondents 
supporting the particular treatment is shown within the bars; their 
length reflects proportion of positive responses in case of the given 
treatment. For better comprehension, the treatment options are split 
into two main categories (anti-viral and immunomodulatory therapy), 
though the therapeutic effects might be overlapping. *predniso-
lone ≤ 2 mg/kg/d, **high-dose prednisolone (10–30 mg/kg/d)




Ninety-three members of the mailing list from 23 countries 
responded (5% of all contacted individual email accounts) 
(Table 1). The majority of respondents worked in the U.S.A 
(50.5%; Supplementary Table 1, Supplementary Figure S2), 
most of them at university hospitals (88.2%). Over half of 
the respondents were senior healthcare professionals work-
ing in the field of pediatric rheumatology for over 10 years 
(52.7%). About two-thirds indicated personal experience 
with the care of patients with COVID-19.
Treatment strategies in pediatric patients 
with COVID‑19
Eighty-four respondents (90.3%) would consider off-label 
treatment in COVID-19 (Fig. 1).
The first three most commonly suggested therapeutics 
for patients in stage I of COVID-19 were the ribonucleo-
tide analogue remdesivir (48.3%), the macrolide antibiotic 
azithromycin (26.6%) and the antimalarial agent hydroxy-
chloroquine (HCQ; 21.9%). While HCQ and azithromycin 
lost support in the stage II (10.9% for HCQ and 9.4% for 
azithromycin) as well as stage III (6.3% and 12.5%), the use 
of remdesivir was considered beneficial by a similar pro-
portion of respondents (46.7% for both, stage II and III). 
Only relatively few respondents (6.7%) would not recom-
mend remdesivir at all. Indecisiveness with respect to the 
above-mentioned drugs was comparable (17.2% in case of 
HCQ, 25% azithromycin, and 25% for remdesivir). Notably, 
a majority of respondents would use neither HCQ (56.3%) 
nor azithromycin (48.4%) at all. Use of lopinavir–ritona-
vir would be considered by only few respondents (8.3%; 
3.3% and 1.7% for the three disease stages, respectively); 
the majority were undecided (61.7%) or argued against its 
use (26.7%). Administration of convalescent plasma gained 
importance for the respondents throughout the disease pro-
gression (14.3%; 22.2% and 35.0%). However, a relatively 
high proportion of respondents were undecided (40%); only 
a small minority (14.3%) expressed concern and would not 
administer convalescent plasma at all.
A significant proportion of respondents would con-
sider immunomodulatory therapy in the management of 
pediatric COVID-19. Oral corticosteroid therapy (pred-
nisolone ≤ 2  mg/kg/d) was the most frequently chosen 
option (25.4%) in stage I. Its importance to the respond-
ents increased with disease progression (stage II, 67.2%). 
Fig. 2  Opinion on the possible earlier use of particular treatment 
modalities in course of COVID-19 in patients with increased risk 
for severe course of viral infections (n = 72 respondents). Number of 
respondents supporting the given approach is shown at each bar; its 
length reflects proportion of positive responses
Table 1  Respondents’ characteristics
Type of medical setting (n = 93)
University hospital 82 (88.2%)
Other hospital 10 (10.8%)
Out-patient setting 1 (1.1%)






Experience in the field of pediatric rheumatology (n = 92)
  < 5 years 12 (13.0%)
 5–10 years 31 (33.3%)
  > 10 years 49 (52.7%)
Experience with treatment of patients with COVID-19 (n = 92)
 Yes 58 (63.0%)
 1–5 patients 33 (35.5%)
  > 5 patients 25 (26.9%)
 Pediatric patients 47 (50.5%)
 Adult patients 2 (2.2%)
 All age categories 8 (8.7%)
 No 34 (36.6%)
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However, in case of severe disease with cytokine storm and 
multiorgan failure (stage III) high-dose intravenous corti-
costeroid therapy (prednisolone 10–30 mg/kg/d) would be 
preferred (81.7% for the intravenous form versus 35.8% for 
the oral variant). More than half of the respondents consid-
ered administering intravenous immunoglobulins (IVIG) for 
more advanced disease (56.5% for both stages II and III). A 
majority of respondents opted for cytokine blocking strat-
egies in imminent or already active hyperinflammation as 
most important therapeutical approach. Blockade of IL-6 
(tocilizumab, 85.5%) or IL-1 (anakinra 83.6%) in stage III 
was supported by most respondents. Interestingly, in milder 
disease (stage II), IL-1 blockade was considered more fre-
quently (79.5%) as compared to IL-6 blockade (58.8%). 
None of the respondents argued against IL-1-blockade; 
similarly, opposition to IL-6 blockade with tocilizumab 
was low (3.0%). Janus kinase (JAK) or complement (eculi-
zumab) inhibition attracted the least attention as therapeutic 
strategy across disease stages, with highest support in stage 
III (27.4% for JAK-inhibitors and 19.3% for eculizumab). 
With the exception of JAK and complement inhibition, 
most respondents expressed confidence in the efficacy of 
immunomodulatory therapy while the uncertainty fluctuated 
between 4.3 and 10.1%. For the use of JAK (50%) and com-
plement inhibition (59.6%), however, a majority of respond-
ents were undecided.
Next, we asked whether treatment decisions and choice of 
particular drugs would depend on the respondents’ experi-
ence and/or characteristics. The only significant difference 
was found for the use of HCQ (p = 0.025) and azithromycin 
(p = 0.026). More senior colleagues (> 10 years of experi-
ence) would use HCQ and azithromycin more readily (in 
stage I) and were generally less critical of these options.
Treatment approaches in potentially 
immunocompromised patients
When comparing responses concerning treatment of patients 
with increased risk for viral infections with those of other-
wise healthy COVID-19 patients (Fig. 2), our respondents 
would promote an earlier use of antiviral drugs (59.7% of the 
respondents), followed by use of immunoglobulins (41.7%), 
cytokine blockade (37.5%), convalescent plasma (31.9%), 
corticosteroids (27.8%) and oral immunomodulatory drugs 
(23.6%) in the course of the disease. Twelve respondents 
would choose neither of those options.
The choice differences between the participants’ groups 
were not statistically significant.
Approach to pre‑existing anti‑inflammatory, 
immunomodulatory and immunosuppressive 
therapy in patients with AID in the context 
of COVID‑19 pandemic
Fifty-eight respondents (62.4%) submitted their responses 
for this section of the survey. For patients without SARS-
CoV-2 infection or signs of COVID-19, 94.2% of those 
respondents would continue established anti-inflammatory/
immunomodulating therapy. Three respondents would con-
sider reduction or discontinuation of an existing long-term 
therapy in patients with clinically inactive rheumatological 
disease.
In AID patients with proven “mild” (stage I) COVID-19 
(Fig. 3) the following therapies would be continued: immu-
noglobulin therapy (100%), HCQ (94.2%), IL-1 blockade 
with canakinumab and anakinra (72.5% and 79.2%, respec-
tively) and IL-6 blockade (with support of 69.8% respond-
ents). The majority of the respondents would discontinue or 
modify (postpone or reduce a dose) therapies with mTOR-
inhibitors (80%), CTLA-4-blockade (76.5%), mycophenolate 
mofetil (75.5%), BAFF-blockade (75%), IL-12/23-blockade 
(70.8%), calcineurin inhibitors (69.2%), JAK inhibition 
(68.7%), TNF-α blockade (67.9%), methotrexate (64.2%), 
azathioprine (61.5%) and leflunomide (59.6%). Treatment 
with dapsone would be reduced by 46.5% of the respond-
ents. Over 75% of respondents would refrain from initiat-
ing therapy with cyclophosphamide (84.6%) or anti-CD20-
antibodies (74.9%).
Discontinuation of long-term oral corticosteroid therapy 
(≤ 2 as well as > 2 mg/kg/d) would only be considered by 
5.8% of respondents. However, a majority of respondents 
would consider dose reduction (26.9% in ≤ 2 mg/kg/d; 50% 
in > 2 mg/kg/d). As many as 27.5% would discontinue/
refrain from intravenous high-dose “pulse” therapy with 
methylprednisolone, 41.2% would reduce the dose.
The only statistically significant difference between the 
groups of respondents was found in case of IL-6 block-
ade with tocilizumab. The majority of senior colleagues 
(> 10 years of experience in pediatric rheumatology) would 
recommend maintenance of the IL-6 blockade (83.9%) in 
comparison to the less experienced colleagues who would 
endorse this approach in only 50% (p = 0.014).
Discussion
An opinion data of almost one hundred international 
pediatric rheumatologists at the time of peaking COVID-
19 pandemic are presented. Due to the rapid evidence 
evolvement in these unique times may this survey impose 
slightly outdated. However, the growing body of evidence 
regarding treatment options in patients with COVID-19 
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or management strategies of individuals with AID applies 
still mainly to the adult population. Furthermore, the care 
for children and adolescent with COVID-19 as well as the 
approach to the pediatric patients with AID in context of 
the COVID-19 pandemic remains controversial and only 
scarce data on changes in health care of pediatric patients 
with rheumatic diseases are available [33, 34].
Treatment strategies in pediatric patients 
with COVID‑19
In this survey, remdesivir was the most frequently consid-
ered virus-directed drug in pediatric patients (almost 50% 
support throughout all disease stages). Frequent concur-
rent choice of remdesivir and/or cytokine blockade and/or 
corticosteroid therapy points towards possible combination 
strategies. This opinion is very well in line with later pub-
lished data on positive clinical effects in a subset of patients 
with COVID-19 [35–37]. Those findings resulted in an 
emergency use authorization from the US Food and Drugs 
Administration (FDA), including children over 12 years 
of age and/or weighing more than 40 kg [38], followed by 
approval in Europe [39]. Early use during the viral replica-
tion stage seems to be most beneficial [40, 41].
Within the group of immunomodulatory drugs corticos-
teroid use gained the highest respondents’ support, reaching 
35.8% and 81.7% use of oral and intravenous corticosteroids, 
respectively, for patients in stage III. This view corresponds 
with "real life" COVID-19 treatment data worldwide [42] 
and is underpinned by the findings from the RECOVERY 
study on use of dexamethasone [43]. However, a precaution 
is warranted as the application of dexamethasone in this trial 
improved outcome only in those on respiratory support [43].
Cytokine blocking strategy (blockade of IL-1 and IL-6) 
was the most often chosen treatment option for patients with 
clinically severe COVID-19 reaching support of 83.6% and 
85.5% respondents, respectively, for use in stage III. This is 
in line with data from case series and individual case reports 
Fig. 3  Opinion on how to approach established anti-inflammatory/
immunomodulatory treatment in patients with autoimmune/inflam-
matory disease (AID) and confirmed mild COVID-19 disease. The 
number of respondents expressing their opinion on each medication 
is depicted next to the graph; the number of respondents supporting a 
particular approach is shown for each bar; its length reflects the pro-
portion of positive responses. The treatment options are arranged in 
descending order with respect to how strongly physicians felt about 
continuing treatment despite mild COVID-19
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[2, 44, 45], at times in combination with high-dose methyl-
prednisolone [46]. The popularity of anakinra may be based 
on its great potential to control hyperinflammation, but also 
its excellent safety profile including use in patients with bac-
terial sepsis and cytokine storm [47]. In addition, anakinra as 
well as tocilizumab are approved for use in cytokine release 
syndrome (macrophage activation syndrome) from 8 and 
24 months of age, respectively.
The most controversial findings in the survey concern 
HCQ and azithromycin. Results of a small clinical trial at the 
onset of the pandemic showed enhancement of the clearance 
effect on SARS-CoV-2 by addition of azithromycin to HCQ 
therapy [48]. This controversial study contributed to opti-
mism and broad uncritical endorsement of HCQ and azithro-
mycin in treating COVID-19. However, growing evidence 
from controlled clinical trials [49–52] did not show conclu-
sive benefit of the therapy. Moreover, cardiotoxicity, namely 
rhythm disorders, became an increased concern among adult 
patients [53, 54]. Currently, HCQ and/or azithromycin are 
not recommended for treatment of COVID-19. Participants 
of this survey were rather hesitant about using HCQ and/or 
azithromycin in COVID-19; however, still around a quarter 
of them would consider their use in the stage I. The dynam-
ics of opinion change and growing skepticism towards these 
treatment modalities could be demonstrated when compared 
to a related, but previous survey that we performed among 
German-speaking pediatric rheumatologists [55].
Recently, it has been shown that the immunocompro-
mised state of patients with primary immunodeficiency is 
not a predominant factor for severe course of COVID-19 
[22]. With exception of deficiency in type I interferon signal-
ing [22, 56] or presence of autoantibodies against interferons 
[57]. Secondary immunodeficiency due to chemotherapy in 
pediatric patients treated for malignant disease is associated 
with longer viral clearance; however, with only minimally 
increased risk of severe course of COVID-19 [58]. Thus, the 
current available data do not justify therapy intensification 
against SARS-CoV-2 infection in all immunocompromised 
children considered by some of our respondents and support 
individualized approach.
Approach to pre‑existing anti‑inflammatory, 
immunomodulatory and immunosuppressive 
therapy in patients with AID in the context 
of COVID‑19 pandemic
Support for the continuation of pre-existing immunomodu-
latory and/or immunosuppressive therapy in patients with 
AID without proven COVID-19 documented in the survey 
is in line with recommendations of the American College of 
Rheumatology (ACR) [30] as well as the European societies 
[31, 59] published after closure of this survey.
In the case of an incipient COVID-19 disease, almost all 
respondents were in favor of continuing ongoing therapy 
with HCQ and subcutaneous or intravenous immunoglobu-
lins for the underlying rheumatological disease. In fact, there 
is no evidence for a disadvantage of these drugs in the con-
text of COVID-19 [60]. The majority of colleagues would 
also continue a pre-existing oral steroid therapy, however, 
reduce higher dosages beyond 2 mg/kg/d. The ACR rec-
ommends continuation of long-term steroid therapy taking 
into account the risk of potential adrenal cortex insufficiency 
(with a pre-treatment period of > 14 days) [30]. The major-
ity of respondents argued against immediate termination of 
IL-1 or IL-6 inhibition. Discontinuation of a short-acting 
IL-1-targeted therapy such as anakinra, carries the risk of 
a rebound phenomenon of the underlying (systemic) rheu-
matic or inflammatory diseases. Moreover, it may trigger a 
macrophage activation syndrome, a complication was also 
observed in some COVID-19 patients [61]. Data supporting 
continuation of IL-1-blockade during mild COVID-19 has 
been recently published: a mild course of the infection was 
shown in three children and one adult treated for autoinflam-
matory disease with IL-1-targeted therapy [62]. After recov-
ery from the infection two out of the three pediatric patients 
suffered from an increased autoinflammatory activity. Those 
flares were presumably due to the underlying disease and not 
related to the IL-1-targeted therapy [62].
A large number of respondents favors a continuation of 
dapsone, mycophenolate, leflunomide, methotrexate, azathi-
oprine and calcineurin-inhibitors, possibly administered in 
reduced dosages. Presumably, antiproliferative drugs would 
be continued for fear of a severe relapse, e.g. in connective 
tissue diseases and vasculitides. In COVID-19 patients-
receiving ongoing immunomodulating/suppressive drugs, 
close monitoring of blood count changes, liver and kidney 
toxicity and, parameters such as IgG, IgM and CD4 T-cell 
numbers are justified [63].
The majority of respondents would pause TNF-alpha 
inhibitors and IL-12/23-inhibitors in COVID-19 patients. 
As in other virus infections, this is a standard approach for 
patients with inactive juvenile (psoriatic) arthritis due to the 
fast effect at restart of TNF-alpha inhibitors post-infection. 
Moderate-to-highly immunosuppressive agents with long 
half-lives such as cyclophosphamide, anti-CD20 and anti-
BAFF antibodies, CTLA-4 IgG would be omitted or dis-
continued [1].
The data published after closure of the survey do not 
show substantially increased risk of infection or severe 
course of COVID-19 in AID patients-receiving immunosup-
pressive and/or biologic treatment [64–66]. A possibly less 
stringent approach regarding the long-term immunomodu-
latory therapy than suggested from our respondents might 
be required.
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Limitations
The results of this survey depict personal therapeutic deci-
sion-making perspectives amid COVID-19 pandemics. The 
heterogeneity of the clinical scenarios and possible (com-
bination) therapies were not explicitly addressed. Some of 
the respondents had no or limited experience in treating 
COVID-19 patients so that the statements are partially based 
on hypothetical considerations. The results are based on par-
ticipation of relatively large group of specialists; however, a 
non-response bias has to be taken into account as majority of 
the addressed experts did not respond. Similarly, the unequal 
distribution of geographical origin of the respondents may 
affect the overall result. Thus, our conclusions are prelimi-
nary and not meant as treatment recommendations.
Conclusions
There is a growing evidence that pediatric patients with AID 
receiving immunomodulatory therapy are not substantially 
endangered by SARS-CoV-2 beyond the common risk of 
viral infections. Responses from this survey are largely in 
line with the evolving findings and endorse continuation of 
most of the immunomodulatory therapies in case of mild 
COVID-19. While a severe or complicated course of acute 
COVID-19 in pediatric population remains rare, the hyper-
inflammatory state (PIMS-TS/MISC) constitutes a signifi-
cant clinical challenge and requires continuous attention and 
further research.
Supplementary Information The online version contains supplemen-
tary material available at https ://doi.org/10.1007/s0029 6-021-04824 -4.
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